Moderna, Inc. $MRNA Shares Purchased by Corient Private Wealth LLC

Corient Private Wealth LLC increased its position in Moderna, Inc. (NASDAQ:MRNA) by 24.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,805 shares of the company’s stock after acquiring an additional 6,751 shares during the period. Corient Private Wealth LLC’s holdings in Moderna were worth $1,026,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its position in Moderna by 21.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,153 shares of the company’s stock valued at $63,000 after buying an additional 387 shares during the last quarter. Sankala Group LLC purchased a new position in Moderna during the 4th quarter worth approximately $240,000. Virtu Financial LLC acquired a new stake in Moderna during the 4th quarter valued at approximately $2,425,000. Hamilton Wealth LLC purchased a new stake in shares of Moderna in the 4th quarter valued at $3,098,000. Finally, Alberta Investment Management Corp purchased a new stake in shares of Moderna in the 4th quarter valued at $1,416,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insiders Place Their Bets

In related news, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at $3,373,400. This represents a 4.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 125,088 shares of company stock worth $6,193,713. 10.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. UBS Group reissued a “neutral” rating on shares of Moderna in a report on Tuesday, May 26th. Piper Sandler increased their price target on Moderna from $69.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, June 26th. Morgan Stanley set a $33.00 price objective on Moderna in a research note on Friday, May 1st. Barclays boosted their price objective on Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. Finally, Jefferies Financial Group restated a “hold” rating on shares of Moderna in a research note on Thursday, June 18th. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $37.13.

Moderna Stock Up 10.0%

MRNA stock opened at $79.76 on Friday. Moderna, Inc. has a one year low of $22.28 and a one year high of $81.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. The firm’s fifty day moving average is $53.02 and its 200 day moving average is $47.87. The firm has a market cap of $31.65 billion, a PE ratio of -9.79 and a beta of 0.94.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. During the same quarter last year, the company posted ($2.52) EPS. The company’s revenue was up 260.2% on a year-over-year basis. On average, research analysts forecast that Moderna, Inc. will post -6.51 EPS for the current year.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.